CTMX CytomX Therapeutics Inc

Price (delayed)

$1.45

Market cap

$112.98M

P/E Ratio

7.25

Dividend/share

N/A

EPS

$0.2

Enterprise value

$88.75M

CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. CytomX is developing a novel class of investigational conditionally activated antibody therapeutics, ...

Highlights
CytomX Therapeutics's net income has surged by 123% YoY
The EPS has soared by 119% YoY
CTMX's quick ratio is down by 17% year-on-year

Key stats

What are the main financial stats of CTMX
Market
Shares outstanding
77.92M
Market cap
$112.98M
Enterprise value
$88.75M
Valuations
Price to earnings (P/E)
7.25
Price to book (P/B)
N/A
Price to sales (P/S)
1
EV/EBIT
4.33
EV/EBITDA
3.37
EV/Sales
0.74
Earnings
Revenue
$119.18M
EBIT
$20.47M
EBITDA
$26.34M
Free cash flow
-$92.34M
Per share
EPS
$0.2
Free cash flow per share
-$1.13
Book value per share
-$0.47
Revenue per share
$1.45
TBVPS
$2.23
Balance sheet
Total assets
$184.69M
Total liabilities
$216.37M
Debt
$12.87M
Equity
-$31.68M
Working capital
$22.71M
Liquidity
Debt to equity
-0.41
Current ratio
1.16
Quick ratio
1.14
Net debt/EBITDA
-0.92
Margins
EBITDA margin
22.1%
Gross margin
100%
Net margin
13.9%
Operating margin
9.1%
Efficiency
Return on assets
8.1%
Return on equity
N/A
Return on invested capital
63%
Return on capital employed
51%
Return on sales
17.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CTMX stock price

How has the CytomX Therapeutics stock price performed over time
Intraday
0%
1 week
-3.97%
1 month
12.4%
1 year
-18.99%
YTD
-6.45%
QTD
18.85%

Financial performance

How have CytomX Therapeutics's revenue and profit performed over time
Revenue
$119.18M
Gross profit
$119.18M
Operating income
$10.83M
Net income
$16.53M
Gross margin
100%
Net margin
13.9%
CytomX Therapeutics's net income has surged by 123% YoY
The operating income has soared by 114% year-on-year
CTMX's net margin has surged by 113% year-on-year
The company's operating margin has surged by 108% YoY

Growth

What is CytomX Therapeutics's growth rate over time

Valuation

What is CytomX Therapeutics stock price valuation
P/E
7.25
P/B
N/A
P/S
1
EV/EBIT
4.33
EV/EBITDA
3.37
EV/Sales
0.74
The EPS has soared by 119% YoY
CTMX's equity has surged by 63% year-on-year and by 33% since the previous quarter
The stock's P/S is 83% less than its 5-year quarterly average of 5.8 and 23% less than its last 4 quarters average of 1.3
CTMX's revenue has surged by 76% year-on-year and by 18% since the previous quarter

Efficiency

How efficient is CytomX Therapeutics business performance
CTMX's return on assets has surged by 128% year-on-year
The ROS has soared by 116% YoY
The ROIC has soared by 113% YoY

Dividends

What is CTMX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTMX.

Financial health

How did CytomX Therapeutics financials performed over time
CTMX's total assets is 15% less than its total liabilities
The company's total liabilities fell by 33% YoY and by 13% QoQ
CTMX's total assets is down by 21% YoY and by 8% from the previous quarter
CTMX's debt is 141% greater than its equity
The debt to equity has dropped by 173% year-on-year and by 41% since the previous quarter
CTMX's equity has surged by 63% year-on-year and by 33% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.